The term "cold chain" refers to the maintenance of consistent temperatures for refrigerated vaccines from manufacture through delivery to health care facilities.

Syracuse University

University of California, Santa Cruz

- manufacturer engagement in developing vaccine
- regulating organizations
- cold chain
- various production platforms

Factors involved in Manufacturing

Vaccine development comes with a host of problems that slows down the progression of producing one. Aside from the economic and time-sensitive factors, vaccines come with alternative effects that need to be studied and approved by national organizations (FDA) for general use:
- Antibody-dependent-enhancement (ADE)
- Comorbidities 
- Challenge studies

Challenges to vaccine development

Shin, M.D., Shukla, S., Chung, Y.H. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646–655 (2020). doi: 10.1038/s41565-020-0737-y

https://doi.org/10.1038/s41565-020-0737-y

COVID-19 vaccine development and a potential
nanomaterial path forward

DCVMN, or the Developing Countries Vaccine Manufacturers Network, is a cohort of 41 multinational vaccine manufacturers in Africa, the Middle East, Latin America, and Asia involved in vaccine development from the research to supply stages. The manufacturers work to benefit both local communities as well as international consumers, and they have contributed to the efforts against coronavirus. 13 of the DCVMN organizations have an understanding of international regulations for supply, as well as vaccines with WHO-prequalified vaccine status. 

DCVMN Involvement

Regulating Organizations

Cold Chain for Vaccines

Features of production platforms for vaccine manufacture

Antibody-dependent enhancement occurs when the antibodies the viruses bind to on the host cell permit increased entry and replication of the virus. This process has been observed in: yellow fever, zika virus, and the novel coronavirus.
ADE affects vaccine development by being a possible unforeseen phenomenon that could cause the vaccine to worsen the patient's condition rather than providing an inflammatory response.

Aid in developing treatments by performing studies of natural disease progression in a controlled environment. They guarantee uniform exposure to speed up vaccine development by reducing ineffective candidates.

Learn Before

Related